The evolution and impact of the American College of Chest Physicians consensus statement on antithrombotic therapy.
The evolution of the American College of Chest Physicians consensus on antithrombotic therapy is reviewed, specifically with regard to the prevention and treatment of venous thromboembolism and the rules of evidence applied. A perspective on the impact of the recommendations is offered.
Tapson
Victor F
VF
Division of Pulmonary and Critical Care, Box 31175, Room 351, Bell Building, Duke University Medical Center, Durham, NC 27710, USA. tapso001@mc.duke.edu
D001458:Bandages; D003245:Consensus Statements as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000517:prevention & control*; D012955:Societies, Medical; D016306:Vena Cava Filters; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin